TEVA:TASETeva Pharmaceutical Industries Limited Analysis

Teva’s stock is trading at $31.64, comfortably above its 200‑day SMA of $23.36 but below the 20‑day ($33.38) and 50‑day ($32.97) averages, indicating a longer‑term bullish bias with short‑term pressure. The RSI of 38 points to modest downside momentum, while the MACD remains in a bearish configuration, suggesting that any breakout may need to clear the near‑term resistance at $35.32. Volume is on an increasing trend and the Fear & Greed Index reads “Extreme Greed” at 79.98, reflecting strong market appetite. Support sits at $29.92, offering a cushion that could trigger a bounce if buying interest resurfaces.
Fundamentally, TEVA delivered $17.26 B in revenue with 11.4% growth, healthy gross margins (51.8%) and operating margins (27.3%). Forward EPS of $3.10 translates to a forward P/E of 10.2, well below the sector average, and analysts’ median price target of $39 implies roughly 20% upside. However, the balance sheet is levered (Debt/Equity ≈ 218) and the company pays no dividend, so cash‑flow sustainability and debt servicing remain focal points.